Trial
LIBERTY AD
Dupilumab clinical-trial programme in atopic dermatitis.
Also called: LIBERTY AD SOLO, dupilumab atopic dermatitis pivotal trial
Sparsely connected — only 1 link recorded so far.
In short
- 1What it is: a trial in therapies and applications.
- 2How it connects: acts on 1 and is affected by 0 concepts — mostly 1 therapy.
- 3Where it sits: trial on the 15-step immune chain.
What it does
SOLO 1 (N=671) + SOLO 2 (N=708); dupilumab 300mg Q2W vs placebo in moderate-severe AD; IGA 0/1 clear/almost clear: 38% vs 10% (SOLO-1); EASI-75: 51% vs 15%; established dupilumab as transformative AD therapy; launched the type-2 inflammation biologic era
Its connections at a glance
Each dot is a concept directly linked to LIBERTY AD. Colours show the kind of concept.
Learn next
Sources & evidenceloading…
Loading reviewed sources…
Graph ID TR005 · concept status: established. Select any connection above to inspect evidence for that specific link.